Table 3 Disease severity assessment of the L-T4 treated and untreated THOP patients
L-T4 Treated | L-T4 Untreated | p valuea | |
|---|---|---|---|
Participants, n | 36 | 47 | |
Medicine | |||
Vancomycin + amikacin | 10 (28) | 5 (11) | 0.044 |
Ampicillin + gentamicin | 13 (36) | 26 (55) | 0.082 |
Caffeine | 34 (94) | 36 (77) | 0.027 |
Dobutamine | 6 (17) | 4 (9) | 0.258 |
Dopamine | 15 (42) | 7 (15) | 0.006 |
Clinical-diagnosis | |||
Sepsis | 5 (14) | 5 (11) | 0.652 |
PDA | 9 (25) | 8 (17) | 0.372 |
RDS | 28 (78) | 23 (49) | 0.007 |
IVH | 18 (50) | 11 (23) | 0.022 |
BPD | 23 (64) | 14 (30) | 0.002 |
ROP | 1 (3) | 2 (4) | 0.363 |
NEC | 1 (3) | 1 (2) | 1.000 |
Clinical interventions | |||
Central catheter | 35 (97) | 34 (72) | 0.003 |
ES transfusion | 15 (42) | 12 (26) | 0.120 |
TS transfusion | 7 (19) | 3 (6) | 0.070 |
FFP transfusion | 18 (50) | 11 (23) | 0.012 |
Ventilator support | 22 (61) | 18 (38) | 0.039 |
NIV support | 24 (67) | 28 (60) | 0.508 |